Key result
Using the novel S2Tag for site-specific surface attachment, the S532P dilated cardiomyopathy mutation resulted in a 60% decrease in actin gliding speed (0.62 vs 1.69 μm/s, p<0.0001) while producing comparable force to wild-type.
Why the study?
The quality and reproducibility of single-molecule and ensemble motility assays of myosin activity require an effective mode of surface attachment.
The S2Tag provides a robust, specific method for immobilizing human β-cardiac myosin in in vitro assays, enabling precise mechanical characterization of wild-type and disease-causing mutant myosins.
S532P selectively impairs myosin velocity in DCM models; leaves open mechanistic roles and therapeutic targeting pending human validation.
Single-molecule and ensemble motility assays are powerful tools for investigating myosin activity. A key requirement for the quality and reproducibility of the data obtained with these methods is the mode of attachment of myosin to assay surfaces. We previously characterized the ability of a monoclonal antibody (10F12.3) to tether skeletal muscle myosin to nitrocellulose-coated glass. Here, we identify the 11 amino acid epitope (S2Tag) recognized by 10F12.3 in the coiled-coil S2 domain of myosin. To test the transferability of S2Tag, we inserted it into a wild-type β-cardiac myosin construct (WT-βCM) and evaluated its mechanochemistry. WT-βCM immobilized via S2Tag robustly propelled actin filaments in gliding assays and showed single-molecule actin displacements and attachment kinetics by optical trapping. Thus, the antibody attachment is effective for ensemble and single-molecule assays. We inserted the S2Tag into a βCM construct containing a penetrant mutation (S532P-βCM) that causes dilated cardiomyopathy. Inclusion of S2Tag enabled quantitative mixed-motor gliding filament assays with WT-βCM. The analysis shows the S532P mutation results in a 60% decrease in gliding speed, yet the motor seems to produce the same force as WT-βCM. Importantly, S2Tag is a useful new tool for affinity capture of alpha-helical coiled coil proteins.
No takes yet. Share an insight, caveat, or question.
Barua et al. (2025) studied Dilated cardiomyopathy (preclinical model). S532P mutated human β-cardiac myosin vs. Wild-type human β-cardiac myosin was evaluated on Actin filament gliding speed (μm/s) (p=<0.0001). Using the novel S2Tag for site-specific surface attachment, the S532P dilated cardiomyopathy mutation resulted in a 60% decrease in actin gliding speed (0.62 vs 1.69 μm/s, p<0.0001) while producing comparable force to wild-type.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: